Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Survival outcomes in POD1UM-303/InterAACT-2: a phase 3 study of retifanlimab plus carboplatin-paclitaxel in first-line advanced squamous anal cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Same author

Advancing Drug Risk Assessment with Tissue Models: Correlating QT Interval and APD90 Prolongation to Refine Proarrhythmic Risk Guidelines.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2025

Same author

Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER-positive/HER2-negative breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Same author

Salvage brachytherapy for local recurrence of cancer after definitive irradiation: a GEC-ESTRO narrative review.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2025

Same author

Regorafenib combined with irinotecan as second-line treatment in metastatic gastro-oesophageal adenocarcinomas: results of PRODIGE 58-UCGI35-REGIRI Unicancer randomised phase II study.

ESMO open·2025

Same author

Reply to Letter to the Editor: 'A phase III randomised trial on the addition of a contact x-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 years results of the OPERA trial' by J. Meyer, T. Koessler.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Search research articles

Related Experiment Video

Updated: Dec 15, 2025

Stereotactic Radiosurgery for Gynecologic Cancer

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

Stereotactic Pelvic Reirradiation for Locoregional Cancer Relapse.

R Kinj¹, J Doyen², J M Hannoun-Lévi²

¹Department of Radiation Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Clinical Oncology (Royal College of Radiologists (Great Britain))

|July 10, 2020

Summary

Stereotactic body radiotherapy (SBRT) reirradiation is a safe and effective treatment for pelvic oligometastatic recurrences. While effective, larger tumor sizes may correlate with poorer outcomes and increased toxicity.

Keywords:

Pelvic radiotherapy pelvic reirradiation reirradiation stereotactic radiotherapy

More Related Videos

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Related Experiment Videos

Last Updated: Dec 15, 2025

Stereotactic Radiosurgery for Gynecologic Cancer

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Area of Science:

Oncology
Radiation Oncology
Medical Physics

Background:

Locoregional recurrence after pelvic radiation affects up to 40% of patients.
Stereotactic body radiotherapy (SBRT) offers an ablative approach suitable for reirradiation in the oligometastatic setting.

Purpose of the Study:

To evaluate the outcomes of SBRT reirradiation for extraosseous pelvic recurrences.
To assess the safety and efficacy of this treatment modality.

Main Methods:

Single-institution retrospective study of 30 patients treated with SBRT pelvic reirradiation (Jan 2011-Feb 2018).
Exclusion criteria included >5 oligometastatic lesions, lesions >7 cm, and intraprostatic recurrence.
Median follow-up was 29.4 months; typical dose was 35 Gy in five fractions.

Main Results:

Common primary sites were rectum and prostate (30.8% each).
Median time to reirradiation was 48 months; median GTV size was 10.2 ml.
12-month local relapse-free survival was 67.7%, metastasis-free survival 67%, progression-free survival 34.8%, and overall survival 83.2%.

Conclusions:

SBRT pelvic reirradiation is a safe and effective option for oligometastatic patients.
Larger tumor size may be associated with worse oncological and toxicity outcomes, warranting careful consideration.